A photo of Joel Sorger.

Joel I. Sorger, MD

  • Co-Director, Sarcoma Program
  • Director, Pediatric Joint Replacement Surgery
  • Associate Professor, UC Department of Pediatrics
I want families to know that I am always available to them. I make myself accessible to answer their questions or talk about whatever is on their mind.

About

Biography

My dad inspired me to become a doctor. And now, when I work with children and families, I treat them like they are part of my own family.

As a pediatric orthopedist, I specialize in caring for children with cancer and in providing joint replacement surgery.

I want families to know that I am always available to them. I make myself accessible to answer their questions or talk about whatever is on their mind.

My research focuses on cancer survival in children.

When I’m not at work I enjoy playing golf and spending time with my family.

BS: Biology, University of Richmond, VA, August 1983-May 1987.

MD: Medical College of Virginia, Richmond, VA, August 1987-May 1991.

Intern: General Surgery Intern, University of Cincinnati, Cincinnati, OH, July 1991-June 1992.

Residency: General surgery resident, University of Cincinnati College of Medicine, 1992-1993; Orthopaedic surgery resident, University of Cincinnati College of Medicine, 1994-1998.

Fellowship: Orthopaedic research fellow, Noyes-Giannestras Biomechanics Lab, University of Cincinnati Department of Aerospace Engineering, 1993-1994; Bone and Soft Tissue Sarcoma Management Fellowship (Orthopaedic Oncology), Harvard University, Massachusetts General Hospital and Boston, Children’s Hospital, August 1998-July 1999.

Certification: American Board of Orthopaedic Surgeons.

Interests

Orthopaedic oncology (sarcoma surgery) and joint replacement surgery

Services and Specialties

Orthopaedic Surgery, Hemangioma and Vascular Malformations, Sarcoma, Hip Preservation

Research Areas

Orthopaedics

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial. Prophylactic Antibiotic Regimens in Tumor Surgery , ; Ghert, M; Schneider, P; Guyatt, G; Thabane, L; Vélez, R; O'Shea, T; Randall, RL; Turcotte, R; Wilson, D; et al. JAMA Oncology. 2022; 8:345-353.

Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY): a multi-center randomized controlled study comparing alternative antibiotic regimens in patients undergoing tumor resections with endoprosthetic replacements-a statistical analysis plan. Schneider, P; Heels-Ansdell, D; Thabane, L; Ghert, M; Bhandari, M; Deheshi, B; Guyatt, G; Holt, G; O’Shea, T; Randall, RL; et al. Trials. 2021; 22.

Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib. Sadaf, A; Szabo, S; Ferguson, K; Sorger, JI; Sumegi, J; Bridge, JA; Pressey, JG. Cancer. 2021; 127:4124-4130.

Implant Survival and Clinical Outcomes of Total Hip Arthroplasty in Adolescent and Young Adult Patients. Zeitlinger, L; Gemayel, A; Whitlock, P; Sorger, J. 2021; 05:062-069.

A large intermuscular shoulder lipoma causing pain and weakness in an 87-year-old patient: a case report. Hasan, SS; O'Loughlin, JP; Sorger, JI. JSES International. 2021; 5:154-157.

Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations. Todd, K; Kim, HK; Szabo, S; Johnson, S; Pressey, J; Nagarajan, R; Sorger, J; Dasgupta, R; Turpin, B. Pediatric Blood and Cancer. 2020; 67.

Orthopedic issues in vascular anomalies. Spencer, SA; Sorger, JI. Seminars in Pediatric Surgery. 2020; 29.

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Weiss, AR; Chen, Y; Scharschmidt, TJ; Chi, Y; Tian, J; Black, JO; Davis, JL; Fanburg-Smith, JC; Zambrano, E; Anderson, J; et al. The Lancet Oncology. 2020; 21:1110-1122.

A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823. Laetsch, TW; Ludwig, K; Barkauskas, DA; DuBois, SG; Ronan, J; Rudzinski, ER; Memken, A; Sorger, J; Reid, JM; Bhatla, T; et al. Journal of Clinical Oncology. 2020; 38:tps10560-tps10560.

Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology. Weiss, AR; Chi, Y; Chen, Y; Choy, E; Davis, JL; Fanburg-Smith, J; Hawkins, DS; Kayton, M; Million, L; Okuno, SH; et al. Journal of Clinical Oncology. 2019; 37:11002-11002.

From the Blog


COVID-19 School Study in JAMA Tops Most-Shared Findings From July 2020
Infectious Diseases and Vaccines

COVID-19 School Study in JAMA Tops Most-Shared Findings From July 2020

Joel I. Sorger, MD, Katherine A. Auger, MD, MSc ...8/11/2020

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey